설명
Azithromycin may interact modestly with adalimumab-treated patients through immunomodulatory properties, though direct pharmacokinetic interaction is minimal and the combination is used routinely in clinical practice.
기전
Azithromycin has anti-inflammatory immunomodulatory properties (reduces TNF-alpha, IL-6, and NF-kB); this may produce modest additive immunosuppressive activity with adalimumab. No relevant pharmacokinetic pathway is shared.
임상적 중요성
No clinically significant adverse interaction documented in post-marketing surveillance; azithromycin is commonly prescribed for respiratory infections in biologic-treated patients.
관리 방법
No specific precautions required; monitor for clinical signs of infection resolution; do not delay necessary antibiotic treatment due to theoretical immunomodulatory overlap.